On June 3, 2026 IN8bio, Inc. (NASDAQ: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers (TCEs) for cancer and autoimmune diseases, reported the publication of a review article titled: "Harnessing γδ T cells through engineering and combination therapies" in the journal Nature Communications. IN8bio Chief Scientific Officer (CSO) Lawrence Lamb, Ph.D. was a contributing author to the review, which highlights advances in γδ T cell engineering, combination approaches, and clinical development strategies designed to improve anti-tumor efficacy across both solid tumors and hematologic cancers.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

γδ T cells differ from conventional alpha-beta T cells through their ability to recognize stress-associated signals independent of major histocompatibility complex (MHC) restriction. This potentially solves problems associated with therapeutic development and enables them to target tumors that evade traditional immune responses. The publication reviews emerging engineering strategies, including CAR-γδ T cells, cytokine-armored γδ T cells, TCE approaches, and antibody-secreting γδ T cells, as well as combination approaches involving checkpoint inhibitors, chemotherapy, cytokines, and bispecific antibodies.

"We are pleased Nature Communications published this review highlighting the rapid progress and growing momentum across the γδ T cell field," said Lawrence Lamb, CSO and scientific co-founder of IN8bio. "The publication highlights the unique biological properties of γδ T cells and their potential to address important limitations associated with current immunotherapy approaches, particularly in difficult-to-treat solid tumors. We believe advances in engineering, manufacturing, and combination strategies are continuing to expand the therapeutic potential of γδ T cells across oncology and autoimmune diseases."

The publication also highlights the potential for allogeneic "off-the-shelf" γδ T cell therapies due to the cells’ lack of graft-versus-host disease (GvHD)-associated alloreactivity, as well as growing clinical evidence supporting γδ T cell therapies across hematologic malignancies and solid tumors, including glioblastoma.

In addition, the review discusses how γδ T cells may function as orchestrators of immune surveillance through their ability to recognize heterogeneous tumor-associated stress signals and potentially overcome mechanisms of immune escape commonly observed in advanced cancers.

This review was authored by an international group of five highly respected oncologists and immunologists including Lawrence Lamb, PhD and IN8bio’s Scientific Advisory Board (SAB) member Jonathan Fisher, BM, PhD, MRCPCH from University College London. There are an increasing number of actively recruiting γδ T cell clinical trials globally, reflecting growing academic and industry interest in the platform across cancer and autoimmune diseases.

(Press release, In8bio, JUN 3, 2026, View Source [SID1234666406])

On June 3, 2026 Cardiff Oncology presented its corporate presentation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(Presentation, Cardiff Oncology, JUN 3, 2026, View Source [SID1234666405])

On June 2, 2026 Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") and United Imaging Healthcare North America, Inc. ("United Imaging") reported the signing of a Memorandum of Understanding (MOU) to evaluate a strategic research collaboration in the United States (U.S.) focused on advancing integrated theranostics solutions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The companies will evaluate the combination of United Imaging’s scanner platforms, software, connectivity and AI capabilities with Telix’s molecular imaging portfolio and validated clinical protocols. The collaboration will explore how a unified approach can drive theranostic workflow efficiencies and standardization by:

Enhancing integration between imaging systems and radiopharmaceutical workflows.
Enabling consistent, protocol-driven imaging performance across systems and sites.
Supporting treatment planning, monitoring, and longitudinal patient management.
Advancing data-driven and AI-enabled clinical decision support tools.
Jeffrey M. Bundy, Ph.D., President & Chief Commercial Officer, United Imaging Healthcare North America, said: "Theranostics represents a fundamental shift toward more integrated and personalized cancer care. Through this collaboration with Telix, we aim to explore how deeply integrated imaging, AI, and radiopharmaceutical workflows can be combined to support routine clinical use at scale."

Kevin Richardson, CEO, Telix Precision Medicine, added, "Realizing the full potential of theranostics requires close alignment between state-of-the-art scanners, integrated software solutions, and radiopharmaceutical innovation. By working with United Imaging, we are exploring new ways to deliver more seamless, data-driven workflow solutions that can support clinicians in their decision making, leading to better patient outcomes."

The collaboration will initially focus on TLX101-Px (Pixclara1, Floretyrosine F 18) in the U.S, with potential expansion into additional markets, and other Telix products and product candidates, subject to mutual agreement. Early efforts will include scanning protocol optimization, workflow support tools development and validation, and launching pilot programs aligned with high-impact clinical applications.

About TLX101-Px

TLX101-Px is a PET imaging candidate, which has been granted Fast Track and Orphan Drug designations by the FDA for the characterization of recurrent or progressive glioma from treatment related changes. In April 2026, the U.S. Food and Drug Administration (FDA) accepted Telix’s New Drug Application (NDA) for review, and assigned a PDUFA2 goal date of September 11, 2026.

TLX101-Px targets membrane transport proteins known as L-type amino acid transporters 1 and 2 (LAT1 and LAT2). This enables TLX101-Px to be potentially utilized as a patient selection and response assessment tool for Telix’s LAT1-targeting therapy candidate TLX101-Tx (131I-iodofalan), currently under investigation in the pivotal IPAX-BrIGHT trial in patients with recurrent glioblastoma3. TLX101-Px has not received a marketing authorization in any jurisdiction.

(Press release, Telix Pharmaceuticals, JUN 2, 2026, View Source [SID1234666403])

On June 2, 2026 Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech or the Company), a global leader in cell therapy, reported that promising preliminary clinical data for LB2501, its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL), will be presented during a late-breaking session at the European Hematology Association (EHA) (Free EHA Whitepaper) 2026 Congress, taking place June 11-14, 2026, in Stockholm, Sweden.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The upcoming presentation of Phase 1 LB2501 data in patients with B-cell malignancies represents an important step in advancing in vivo CAR-T approaches," said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. "By generating CAR-T cells directly within the patient, this approach has the potential to simplify treatment delivery and expand access for patients who may not be able to receive traditional CAR-T cell therapies. LB2501 is built on the TaVec platform, which is a proprietary lentiviral vector engineered to enhance T-cell specificity, transduction efficiency, and safety, while restricting transduction of non-T cells."

LB2501: Promising Phase 1 Trial of In Vivo CAR-T Data Demonstrate High Response Rates in B-cell Malignancies

Data from 12 patients across two dose cohorts in an ongoing Phase 1 study evaluating LB2501 in patients with R/R B-NHL provide early clinical evidence supporting the potential of an in vivo CAR-T approach in B-cell malignancies. LB2501 is designed to generate CAR-T cells directly within the patient following a single intravenous infusion, eliminating the need for cell manufacturing and lymphodepletion.

As of April 1, 2026, 12 patients with R/R B-NHL were treated across two dose levels (DL1 and DL2). Additional details will be presented at EHA (Free EHA Whitepaper) 2026. Key findings from the abstract include:

Efficacy Results

At DL2 (median follow-up for DL2 was 2.2 months [range, 2.0 to 3.8])
Objective response rate (ORR): 100% (6/6)
Complete response rate (CR): 83.3% (5/6)
All responses were ongoing at data cutoff

Pharmacokinetics

Dose-dependent in vivo CAR-T expansion observed
CAR-T cells detected in peripheral blood for up to 116 days

Safety Results

No dose-limiting toxicities (DLTs), serious adverse events (SAEs), or deaths were observed
Infusion-related reactions occurred in 75% of patients, all of which were ≤ Grade 2
Cytokine release syndrome (CRS) occurred in 66.7% of patients, all of which were ≤ Grade 2
No immune effector cell-associated neurotoxicity syndrome (ICANS) was reported
Grade ≥3 lentiviral vector-related and CAR-T-related adverse events were limited to decreased lymphocyte count and decreased neutrophil count

EHA Presentation (June 11-14, 2026)

Abstract No. Title Information
Abstract #LB5006
Late-Breaking Oral Presentation First-in-human trial of LB2501, an in vivo CD19/CD20 dual targeting CAR-T therapy, in relapsed/refractory B-Cell NHL

Session ID: s204
Date/Time: Sunday, June 14, 2026, 9:15-10:45 AM CEST
Location: Nobel Hall

ABOUT LB2501
LB2501 is an investigational, potential first-in-class CD19/CD20 dual-targeting in vivo CAR-T therapy designed to generate CAR-T cells directly within the patient following a single intravenous infusion. It is being evaluated in an ongoing Phase 1, open-label study NCT07002112) in patients with relapsed/refractory B-cell malignancies to assess safety, tolerability, and preliminary efficacy.i

ABOUT B-CELL NON-HODGKIN LYMPHOMA
Non-Hodgkin lymphoma (NHL) is a group of cancers that originate in lymphocytes, a type of white blood cell that plays a key role in the body’s immune system.ii B-cell lymphomas account for approximately 85% of NHL cases and arise from abnormal growth of B lymphocytes (B cells), which are responsible for producing antibodies. These malignancies include a range of subtypes that vary in aggressiveness, from slow-growing to highly aggressive disease.

(Press release, Legend Biotech, JUN 2, 2026, View Source [SID1234666402])

On June 2, 2026 Greywolf Therapeutics, a clinical-stage biotech company advancing novel antigen modulation treatments for cancer and autoimmune diseases, reported clinical and translational results from six completed Phase 1b expansion cohorts of the EMITT-1 trial (NCT06923761) evaluating GRWD5769, a first-in-class oral ERAP1 inhibitor, in combination with cemiplimab in patients with secondary anti-PD-1 resistance or microsatellite stable colorectal cancer without liver metastases (MSS-CRC NLM).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Data were presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting by Professor Fiona Thistlethwaite, Consultant Medical Oncologist at The Christie NHS Foundation Trust and Medical Director of the National Institute for Health and Care Research (NIHR) Manchester Clinical Research Facility at The Christie, and Principal Investigator of the EMITT-1 trial.

Professor Fiona Thistlethwaite, Consultant Medical Oncologist at The Christie NHS Foundation Trust and Medical Director of the National Institute for Health and Care Research (NIHR) Manchester Clinical Research Facility at The Christie said:

"What excites me about this trial is the combination of what we’re seeing – strong signals of efficacy across six tumor types that have shown great resistance to immunotherapy, with very few side effects. That’s unusual at such an early stage."

Highlights from the Phase 1b data

Objective Response Rates (ORR) of 13–36% across all six cohorts in patients with a median of 2 prior lines of therapy and documented secondary anti-PD-1 resistance (except MSS-CRC (NLM) where this therapy is not effective)
Durable Clinical Benefit of 18–55% across all cohorts (DCB — defined as complete response, partial response, or stable disease lasting ≥6 months) and Progression Free Survival duration of 33 wks in NSCLC, 16 wks in HCC and 33 wks in MSS-CRC (NLM) (with 8.8 months median follow-up and still maturing). These data are very encouraging in a setting where durable benefit is exceptionally rare.
GRWD5769 is well tolerated in cemiplimab combination, with no safety signals and most adverse events being Grade 1

Evaluable*
(n) Partial response(s) Overall response rate
(%) Durable clinical benefit
(%) Progression-free survival
(wks)
Urothelial carcinoma 14 5 36 36 8
Non-small cell lung cancer 14 3 21 55 33
Hepatocellular carcinoma (liver cancer) 14 2 14 32 16
Microsatellite stable colorectal cancer (no liver metastases) 12 2 17 51 33
Cervical 14 2 14 18 9
Head and neck squamous cell carcinoma 8 1 13 38 14

Tom Lillie, Chief Medical Officer of Greywolf Therapeutics, said:

"Seeing the combination of strong durable clinical benefit rates and sustained PFS in a population that had already failed anti-PD-1 therapy, and in MSS-CRC where it isn’t licensed, is a clinically meaningful signal. Critically, we’re seeing this alongside a tolerability profile that enables patients to remain on treatment for extended periods, providing excellent potential for GRWD5769 to be used in other combination therapies."

Peter Joyce, CEO and Co-founder of Greywolf Therapeutics, said:

"EMITT-1 has validated a mechanism that the field has long recognized as scientifically compelling but clinically unproven. We are now advancing into Stage 2 cohort expansions to inform a randomized Phase 2 study, and we believe this data positions GRWD5769 as a genuinely differentiated approach to two of the largest unmet needs in oncology — T cell exhaustion and tumor visibility to the immune system."

About GRWD5769

GRWD5769 is a first-in-class oral small molecule inhibitor of Endoplasmic Reticulum Aminopeptidase 1 (ERAP1), an enzyme that regulates tumor antigen presentation on MHC-I. By inhibiting ERAP1 on a cyclical Q3W on/off schedule, GRWD5769 aims to generate alternating antigenic repertoires to broaden T cell responses and prevent T cell exhaustion driven by chronic antigen exposure. The drug is administered as an oral capsule in combination with cemiplimab, an approved anti-PD-1 therapy.

About the EMITT-1 trial

EMITT-1 (NCT06923761) is a global Phase 1/2 study evaluating GRWD5769 in combination with cemiplimab across multiple solid tumor types. The Phase 1b expansion enrolled patients across six cohorts: non-small cell lung cancer (NSCLC), urothelial carcinoma (UC), hepatocellular carcinoma (HCC), MSS-CRC (without liver metastases), squamous cell carcinoma of the head and neck (SCCHN), and cervical cancer. All patients had secondary resistance to prior anti-PD-1 therapy, except for the MSS-CRC NLM cohort. The trial is ongoing across 28 centers in Australia, France, Spain, and the United Kingdom.

(Press release, Grey Wolf Therapeutics, JUN 2, 2026, View Source [SID1234666401])